May 19th 2024
With agents like semaglutide and tirzepatide becoming household drug names, Peterson discusses the short-term future of incretin drug development.
COVID-19 Infection Could Increase Risk of Developing Diabetes
July 19th 2022An analysis of data from more than 450,000 patients in the UK details an 81% increase in the net incidence of diabetes in the first 4 weeks after contracting COVID-19, which remained elevated through weeks 5-12, compared to those who did not contract COVID-19.
Medicare Advantage Beneficiaries Less Likely to Receive Newer Diabetes Medications
July 11th 2022An analysis comparing prescribing practices for Medicare Advantage beneficiaries against those in fee-for-service programs suggests Advantage patients were more likely to receive ACE inhibitors or ARBs, but 20% less likely to receive GLP-1 RAs and 9% less likely to receive SGLT2 inhibitors.
Diabetes Can Increase Mortality, Morbidity in Acromegaly
July 9th 2022An analysis from investigators in Sweden suggests patients with acromegaly with diabetes had a 58% greater risk of overall mortality and a more than 2-fold increase in risk of cardiovascular mortality compared to their counterparts without diabetes.
Top FDA Approvals in Diabetes Care from the First Half of 2022
July 1st 2022With the first 6 months of 2022 behind us, Endocrinology Network has compiled a list of the top approvals in diabetes care from the first half of the year. The list includes multiple approvals for CGM, a first-in-class agent, and an increased dose of a popular GLP-1 RA.
Most PCPs Forgo Fundoscopic Exams for Diabetic Retinopathy in T2D Patients
June 30th 2022An analysis from Duke University School of Medicine suggests few PCPs were performing fundoscopy to identify diabetic retinopathy in patients with type 2 diabetes and even those who did were often accurate just 63% of the time.
Study Compares Fracture Risk Among Antidiabetes Medication Regimens
June 27th 2022An analysis of real-world data from more than 6500 patients suggests insulin users had a greater risk of fracture than patients using metformin, but this became attenuated among patients using a combination of insulin and metformin.
Diabetes Dialogue: Prescribing Tirzepatide, Biosimilar Insulins, and Misdiagnosis of T1D
June 24th 2022In this episode, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss their experiences with prescribing tirzepatide (Mounjaro) and what issues patients have encountered, the prospect of new biosimilar insulins that may be coming to the market, and the misdiagnosis of type 1 diabetes in adult patients.
Annual Wellness Visits Linked to Lower Risk of Amputation in Type 2 Diabetes
June 21st 2022An analysis of data from Medicare Fee-for-Service beneficiaries suggests patients attending annual wellness visits were 36% less likely to require lower limb amputation than their counterparts who did not attend an annual wellness visit that year.
Prediabetes Not as Benign as Once Believed, Associated with Increased Risk of Heart Attacks
June 17th 2022An analysis of the National Inpatient Sample details the statistically significant increases in the risk of experiencing myocardial infarction, PCI, or CABG in patients with prediabetes compared to their normoglycemic counterparts.
In Pediatric T1D, Race, Income, & Insurance Type Remain Significant Barriers to Insulin Pump Use
June 14th 2022An analysis of the SEARCH for Youth in Diabetes presented at ENDO 2022 details historic and contemporary disparities in insulin pump use for pediatric type 1 diabetes based on racial/ethnic background, household income, and insurance type.